History

Thymosin alpha-1 traces to the 1960s-70s work of Allan Goldstein, whose laboratory isolated the crude thymic extract "thymosin fraction 5." It was the first peptide purified, sequenced, and synthesized from that fraction, characterized in the mid-to-late 1970s as a 28-amino-acid, N-terminally acetylated peptide. It was commercialized as the synthetic drug thymalfasin under the brand Zadaxin (developed by SciClone Pharmaceuticals). While never FDA-approved in the US, it has been approved in numerous countries, chiefly for chronic hepatitis B and C.

Thymosin Alpha-1 (thymalfasin, sold abroad as Zadaxin) is one of the more genuinely studied peptides on the market. That doesn’t mean it does what wellness clinics claim it does.

What it is

Thymosin Alpha-1 is a synthetic copy of a 28-amino-acid peptide first isolated from the thymus gland, the organ that helps train T cells. It acts as an immune modulator: in the lab it nudges T-cell maturation and dendritic-cell signaling rather than blanket-stimulating the immune system. It is given by subcutaneous injection. Unlike many “research peptides,” it has been through real, large clinical trials over several decades.

The claims

Clinics and sellers promote it for “immune support,” chronic infections, faster recovery, cancer adjuvant therapy, Lyme disease, autoimmune conditions, and general anti-aging. The honest version is much narrower than that list.

What the evidence actually shows

The strongest human data is in chronic hepatitis B. Multiple randomized controlled trials and meta-analyses found it suppresses viral replication and normalizes liver enzymes about as well as older interferon therapy, with better tolerability. But these trials were small (a representative meta-analysis pooled just four trials and about 200 patients), largely enrolled HBeAg-negative patients, came mostly from China, and compared against interferon rather than today’s standard antiviral drugs. It is approved abroad on this evidence, not on modern head-to-head data.

In sepsis, the picture is cautionary. Early meta-analyses suggested lower mortality, but those pooled small, lower-quality trials (for example, the 2013 ETASS trial was single-blind and only marginally significant). The largest and best-designed study to date, the TESTS trial (BMJ, 2025, 1,106 patients enrolled and 1,089 in the primary analysis, double-blind, placebo-controlled), found no reduction in 28-day mortality (hazard ratio 0.99, p=0.93). Subgroup analysis even hinted at possible harm in younger and non-diabetic patients, though subgroups are exploratory and not conclusive.

For COVID-19, an apparent mortality benefit in a retrospective study disappeared once researchers adjusted for how sick patients were. For cancer adjuvant use, Lyme, autoimmune disease, and general “immune support” in healthy people, there is no solid randomized human outcome evidence — the marketing runs far ahead of the science.

Legal and regulatory status

Thymosin Alpha-1 is not approved by the FDA for any use and never has been, despite US hepatitis trials decades ago. It holds orphan-drug designations (including for hepatocellular carcinoma) but those are not approvals. It is approved in roughly 35 other countries as Zadaxin for hepatitis B.

In the US it is available only through compounding pharmacies, and that status has been volatile: the FDA placed it in, then removed it from, its problematic “Category 2” bulk-substances list, and a December 2024 advisory-committee (PCAC) review fed into ongoing rule-making. As of mid-2026 its compounding eligibility remains unsettled — check the current FDA 503A bulk drug substances list rather than a vendor’s claim. Note for athletes: Thymosin Alpha-1 is not on the WADA Prohibited List, unlike the unrelated Thymosin Beta-4 / TB-500, which is banned.

Safety

Across decades of trials in sick patients it has a clean record: the main reported effects are mild, transient injection-site reactions, and occasional headache or flu-like symptoms. The important caveat is that this safety data comes almost entirely from supervised use in people with serious disease — not from healthy adults self-injecting for “longevity,” where long-term effects of nudging immune signaling are simply unstudied. Nothing here is medical advice.

Bottom line

This is a real drug with real but uneven human evidence: reasonably supported in hepatitis B, negative in the best sepsis trial, and unproven for the immune-boosting and anti-aging uses it’s marketed for.

Evidence grade: Preliminary human.